Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (6657)	7/13/1998 12:15:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Everyone agrees that sooner is better. but also once approved this means results from its use might be better than trial results where a delay in treatment is part and parcel of the trial. I never thought BPI bound up all endotoxin. This is dead material and it is not reproducing. The body may/will remove some with its own host defenses and while the remaining endotoxin will do damage I thought that it would be reduced relative to the amount that would have occurred in none was bound up and eliminated by BPI. Someone else can can correct me or put this in more scientific terms.